ICU Medical Inc (ICUI, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. ICU Medical Inc is engaged in the development, manufacture and sale of medical devices used in infusion therapy, oncology and critical care applications. Its products include needlefree connectors, nanoclave, chemoclock, chemoclave, and among others. ICU Medical Inc has a market cap of $5.05 billion; its shares were traded at around $250.80 with a P/E ratio of 75.34 and P/S ratio of 4.88. ICU Medical Inc had annual average EBITDA growth of 7.80% over the past ten years.
For the last quarter ICU Medical Inc reported a revenue of $370.1 million, compared with the revenue of $95.69 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $1.3 billion, an increase of 240.7% from last year. For the last five years ICU Medical Inc had an average revenue growth rate of 24.6% a year.
The reported diluted earnings per share was $3.29 for the year, a decline of 10.1% from the previous year. Over the last five years ICU Medical Inc had an EPS growth rate of 6.7% a year. The ICU Medical Inc had an operating margin of -1.17%, compared with the operating margin of 21.86% a year before. The 10-year historical median operating margin of ICU Medical Inc is 16.70%. The profitability rank of the company is 6 (out of 10).
At the current stock price of $250.80, ICU Medical Inc is traded at 68.5% premium to its historical median P/S valuation band of $148.84. The P/S ratio of the stock is 4.88, while the historical median P/S ratio is 2.92. The stock gained 63.20% during the past 12 months.
For the complete 20-year historical financial data of ICUI, click here.
